Tubulin (vinca alkaloid binding site) (Tubulin)

Tubulin is a heterodimeric protein composed of alpha and beta subunits that polymerize to form microtubules, which are essential for cell structure, intracellular transport, and the formation of the mitotic spindle during cell division (UniProt: P07437). Monomethyl auristatin E (MMAE) is a potent antimitotic agent derived from the natural product dolastatin 10 that binds specifically to the vinca alkaloid binding site, also referred to as the peptide site, on tubulin (PubChem: CID 11542188). This binding interaction inhibits the polymerization of tubulin, preventing the assembly of microtubules and causing the cell cycle to arrest in the G2/M phase (PubMed: 14559587). The resulting mitotic catastrophe leads to the induction of apoptosis in rapidly dividing cells, making it a highly effective mechanism for treating various malignancies. Because of its extreme potency and potential for systemic toxicity, MMAE is most commonly utilized as a cytotoxic payload in antibody-drug conjugates (ADCs), such as brentuximab vedotin and polatuzumab vedotin, which deliver the drug directly to cells expressing specific surface antigens (PubMed: 31073233). This targeted approach maximizes the therapeutic index by concentrating the microtubule-disrupting effect within tumor tissues while sparing healthy cells.

Other names

Vinca alkaloid binding sitePeptide binding site on tubulinDolastatin binding siteMicrotubule binding site

MMAE binds to the vinca alkaloid binding site (peptide site) on tubulin, which inhibits tubulin polymerization and microtubule assembly, leading to G2/M phase cell cycle arrest and apoptosis (PubMed: 14559587; PubChem: CID 11542188).